Key players, such as Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Galapagos, and others, are involved in the development of therapies for the treatment of interstitial lung disease (ILD) patients. The companies are mainly working on the development of novel therapies to mimic the natural immune system and cell-based therapies for the management of Interstitial Lung Disease. The major therapies are Pirfenidone, ATYR1923, Abatacept, OATD-01, and others.
DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Interstitial Lung Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Interstitial Lung Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Interstitial Lung Disease: An Overview
According to the American Lung Association, Interstitial Lung Disease (ILD) is a general term for a large group of disorders that cause scarring or fibrosis of the lungs. Fibrosis or scarring can be part of the healing response to injury, but fibrosis as a disease process occurs when restoration to normal tissue does not occur. The scarring causes stiffness in the lungs, which makes it difficult to breathe. The disease is characterized by the presence of inflammation and altered-lung interstitium. ILDs usually have a gradual onset but can also present an acute course, and lung damage from ILDs is irreversible and progressive; which means it gets worse over time
There are more than 200 different conditions included among the total number of ILDs. In most cases, the causes are unidentified. In some cases, it may be caused by contact with hazardous chemicals, irritants, certain medications, pathogenic infections (with bacteria, viruses, and fungi), and medical treatment. Regardless of the underlying cause, people with ILD share a common clinical presentation which includes distressing dyspnea, exercise intolerance, and persistent cough. Common symptoms of ILDs include shortness of breath, cough, weight loss, fatigue, weakness, and discomfort in the chest, among others.
Interstitial Lung Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Interstitial Lung Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Interstitial Lung Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Interstitial Lung Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Interstitial Lung Disease Epidemiology, Segmented as –
Total Incidence of Interstitial Lung Disease in 7MM (2019–2032)
Gender-specific cases of Interstitial Lung Disease (2019–2032) [Male; Female]
Subtype-specific cases of Interstitial Lung Disease (2019–2032) [Unknown etiology, exogenous etiology, and variable etiology]
Diagnosed and Treatable cases of Interstitial Lung Disease (2019–2032)
Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Interstitial Lung Disease market or expected to be launched during the study period. The analysis covers the Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Interstitial Lung Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Interstitial Lung Disease Market Will Evolve and Grow by 2032 @
Interstitial Lung Disease Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Interstitial Lung Disease. Currently, Pfizer is leading the therapeutics market with its Interstitial Lung Disease drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Interstitial Lung Disease Therapeutics Market Include:
And Many Others
Interstitial Lung Disease Emerging and Marketed Drugs Covered in the Report Include:
DWN12088: Daewoong Pharmaceutical
BMS-986278: Bristol-Myers Squibb
ATYR1923: aTyr Pharma
OATD-01: OncoArendi Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Interstitial Lung Disease Competitive Intelligence Analysis
4. Interstitial Lung Disease Market Overview at a Glance
5. Interstitial Lung Disease Disease Background and Overview
6. Interstitial Lung Disease Patient Journey
7. Interstitial Lung Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Interstitial Lung Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Interstitial Lung Disease Unmet Needs
10. Key Endpoints of Interstitial Lung Disease Treatment
11. Interstitial Lung Disease Marketed Products
12. Interstitial Lung Disease Emerging Drugs and Latest Therapeutic Advances
13. Interstitial Lung Disease Seven Major Market Analysis
14. Attribute Analysis
15. Interstitial Lung Disease Market Outlook (In US, EU5, and Japan)
16. Interstitial Lung Disease Access and Reimbursement Overview
17. KOL Views on the Interstitial Lung Disease Market
18. Interstitial Lung Disease Market Drivers
19. Interstitial Lung Disease Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Services
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States